New drug cocktail shows promise for Tough-to-Treat urinary tract cancer
NCT ID NCT05837806
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This phase 2 trial is testing two drugs—tislelizumab and disitamab-vedotin—given before surgery for a rare cancer of the upper urinary tract (UTUC) that is HER2-positive and high-risk. The goal is to see if the combination can shrink or eliminate tumors, making surgery more effective. About 21 adults will receive three cycles of the drugs intravenously, then undergo standard surgery to remove the affected tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tislelizumab and disitamab-vedotin
- What this could lead to
- If successful, this combination could offer a more effective and less toxic treatment option for patients with this rare cancer before surgery, potentially improving survival.
- What could go wrong
- This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The drugs can cause side effects like immune reactions or nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK HER2-POSITIVE UPPER TRACT UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to shrink rectal tumors and save organs
- New drug combo aims to stop liver cancer recurrence before surgery
- New hope: drug before surgery may stop merkel cell cancer spread
- Can less be more? new study tests smaller lung surgery after immunotherapy
- Chemo-Free hope: new combo before lung surgery shows promise
- New drug combo shows promise in shrinking cervical tumors before surgery